What do midterms mean for Trump's pharma and health agenda?
As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
Newsletters and Deep Dive digital magazine
As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in Q3, says CEO Bill Anderson.
EVERSANA has acquired UK AI-powered health economics and outcomes research (HEOR) firm Estima to help its customers "modernise commercialisation."
Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
The FDA has started its review of uniQure's gene therapy for neurodegenerative disorder Huntington's, but will require an advisory committee meeting.
Editor's Picks
Newsletters and Deep Dive
digital magazine